Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
US Army
Cantor Fitzgerald
Queensland Health
Express Scripts

Generated: December 10, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,217,974

« Back to Dashboard

Summary for Patent: 5,217,974

Title: Method for treating gar-transformylase tumors in mammals and reducing mammalian toxicity
Abstract:Administration of a folate binding protein binding agent in conjunction with use of an antitumor agent which is an inhibitor of glycinamide ribonucleotide transformylase or other antifolate reduces the toxic effects of such agent and provides an enhanced therapeutic index.
Inventor(s): Grindey; Gerald B. (Indianapolis, IN), Shih; Chuan (Carmel, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:07/940,568
Patent Claim Types:
see list of patent claims

No matches for this query

International Patent Family for Patent: 5,217,974

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria126700► Subscribe
Australia640524► Subscribe
Australia8457091► Subscribe
Canada2051520► Subscribe
Cyprus1888► Subscribe
Germany69112376► Subscribe
Denmark0505640► Subscribe
European Patent Office0505640► Subscribe
Spain2077808► Subscribe
Greece3017774► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Johnson and Johnson
Boehringer Ingelheim
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: